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MINIMAL LATE EFFECTS FOLLOWING REDUCED INTENSITY TRANS-
PLANT FOR NON-MALIGNANT DISORDERS
Madden, L.M.1, Shenoy, S.1, Murray, L.1, Witty, S.2, Hayashi, R.J.1
1Washington University School of Medicine, Saint Louis, MO; 2Univer-
sity of Missouri School of Medicine, Columbia, MO
Allogeneic transplant is the only cure for many non-malignant
life-threatening disorders. Reduced intensity conditioning regi-
mens are increasingly employed prior to stem cell transplantation,
but little is known about the late effects of these regimens. We
present here the late effects of a preparative regimen consisting
of Campath-1H, Fludarabine, and Melphalan beyond two years
following transplantation. We have found that the regimen itself
has very few late effects. Using CTCAE v. 4.03 for criteria to clas-
sify the severity of the late effects, out of twenty patients studied,
five patients experienced a grade 1, two patients a grade 2, and
two patients a grade 3 toxicity; no patients experienced a grade
4 toxicity, and one patient experienced a grade 5 toxicity. The
most common regimen-associated toxicity, found in 15% of pa-
tients, was an acquired autoimmune disorder affecting red cells
and neutrophils. One patient developed extensive, chronic
GVHD leading to multi organ system dysfunction, severe linear
growth deceleration, and eventual death. 70% of patients fully en-
grafted, 15% had stable mixed chimerism, and 15% had secondary
graft rejection, one of whom required a second, myeloablative
transplant. The other two were rescued with donor lymphocyte
infusions. There was only one patient with transplant-associated
growth failure, and puberty was acheived in the 25% of patients
who were of age to pass through puberty during and after trans-
plant, indicating that gonadal function was preserved in this pop-
ulation. We did not observe transplant-associated cognitive
impairment. There were two deaths (10%), one (5%) of which
was transplant-related, one (5%) was attributable to a complication
of his underlying disease. Thus, this non-myeloablative regimen
was associated with minimal toxicity two years beyond the trans-
plant procedure, making it an attractive option for patients with,
nonmalignant diseases.LEUKEMIA227
UNIVERSAL MINIMAL RESIDUAL DISEASE QUANTIFICATION USING CON-
SENSUS PRIMERS AND HIGH-THROUGHPUT IGH SEQUENCING PREDICTS
POST-TRANSPLANT CLL RELAPSE BETTER THAN PATIENT-SPECIFIC PCR
Logan, A.C.1, Zhang, M.B.2, Faham, M.3, Carlton, V.3, Zheng, J.3,
Moorhead, M.3, Willis, T.3, Jones, C.D.2, Waqar, A.N.2,
Zehnder, J.L.2, Miklos, D.B.1 1Stanford University School of Medicine,
Stanford, CA; 2Stanford University School of Medicine, Stanford, CA;
3Sequenta, Inc., South San Francisco, CA
Methods for broadening the availability of minimal residual dis-
ease (MRD) quantification in chronic lymphocytic leukemia
(CLL) are needed to improve patient management. Here, we re-
port the performance of consensus primed PCR to amplify immu-
noglobulin heavy chain (IGH) loci from polyclonal B cells in
peripheral blood, followed by high-throughput sequencing
(IGH-HTS) to ascertain CLL burden in patients treated with re-
duced intensity allogeneic hematopoietic cell transplant (HCT).
We achieved 10e-6 MRD sensitivity and found this approach pro-
vides better prediction of relapse than allele-specific quantitative
PCR (ASO-PCR).
We amplified IGH loci from genomic DNA extracted from
PBMC (median input 1.4x10e6 cells; range 0.2-23.7x10e6) using
consensus V and J segment primers. IGH molecules were se-
quenced with one million or more dedicated reads using Illu-
mina HiSeq and clonotypes were quantified with Sequenta
HTS bioinformatics. 289 samples collected prospectively from
42 patients at 10 post-HCT time points (range 0-1090 days)
were analyzed.
CLL-specific IGH clonotypes were identified for 37 patients ei-
ther by Sanger sequencing performed for pre-transplant prognosti-
cation, or by IGH-HTS using disease bearing samples. Fivepatients did not have samples with sufficient disease burden to iden-
tify the CLL clone and have been excluded from analysis. 24 patients
were assessed by ASO-PCR and IGH-HTS, 13 by IGH-HTS alone.
We observed no failures of the IGH-HTS technique to recover
CLL-specific IGH clones, even in patients with somatically mutated
CLL.
With median follow-up of 927 days (range 297-2265 days), 18 pa-
tients (49%) relapsed and 7 (19%) died. Of 17 patients positive for
MRD by IGH-HTS between 270 to 365 days post-HCT, 100% re-
lapsed, whereas 1 of 12 MRD negative patients (8.3%) relapsed (p5
0.0001). In contrast, ASO-PCR negativity during this time frame
was not associated with sustained remission (p 5 0.21). Owing to
its higher sensitivity, the median time to MRD negativity was longer
with IGH-HTS compared with ASO-PCR (365 versus 270 days).
80% of patients who achieved ASO-PCR negativity at any time,
but who never subsequently achieved negativity by IGH-HTS,
relapsed.
IGH-HTS provides heretofore unachievable MRD sensitivity for
patients with CLL. The highly prognostic value of achieving MRD
negativity with 10e-6 sensitivity within one year post-HCTmay pro-
vide a benchmark for treatment success and a basis for further ther-
apy in patients failing to achieve this status.228
FREQUENCY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION AMONG HIGH-RISK AML PATIENTS IN FIRST COMPLETE REMIS-
SION AT AN ACADEMIC CENTER
Pagel, J.M.1,2, Lionberger, J.1,2, Sandhu, R.1, Gooley, T.A.1,2, Shannon-
Dorcy, K.1,2, Dean, C.1, Scott, B.1,2, Sandmaier, B.M.1,2,
O’Donnell, P.1,2, Becker, P.1,2, Petersdorf, S.1,2, Hendrie, P.1,2,
Sorror, M.L.1,2, Holm, N.1, Deeg, J.1,2, Appelbaum, F.R.1,2,
Estey, E.H.1,2 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA
Background: Allogeneic hematopoietic cell transplantation
(HCT) likely prolongs survival in high-risk adults with acute my-
eloid leukemia (AML) in first complete remission (CR1). Prior
studies, however, suggest that only about 15% of AML patients
age $50 with abnormal cytogenetics who entered CR1 at an aca-
demic cancer center received a reduced intensity HCT in CR1
(Estey et al., Blood 2007;109:1395-1400). In this study, only
HLA-matched siblings were primarily used as donors, raising
the question of the frequency with which HCT is performed in
adults of all ages entering CR1 if unrelated donors as well as sib-
lings are utilized. Here we address this question and compare
high- or intermediate-risk AML patients who did and did not re-
ceive HCT while in CR1.
Methods: Between Jan, 1 2008 and March 1, 2011, 244 patients
received treatment for newly-diagnosed AML at our Center and
who achieved CR or CRi [98/117 (84%) in CR and 19/117
(16%) in CRi]. Because HCT is generally not recommended/un-
dertaken in patients age .75 or who have favorable cytogenetic
risk [inversion 16, t(8,21), or t(15;17)] or who are NPM1 mutated
and FLT3 wild-type, we excluded such patients, leaving 117 with
high- or intermediate-risk AML in CR1. Logistic regression was
used to distinguish characteristics associated with receiving HCT
in CR1.
Results: Seventy-nine AML patients (68%; 95% CI 59-76%) re-
ceived HCT in CR1 at a median of 5.1 months (range, 1.2-20
months) from their CR1 date. Characteristics of patients who re-
ceived or did not receiveHCT inCR1 are shown in the Table below:
Table. HCT vs No HCT in CR1
P-value
HCT
(79 pts)
No HCT
(38 pts)logistic
regressionMean Age (range) 53 (18-75) 55 (24-73) 0.54
Mean Performance status
at CR1 (range)1.1 (1-2) 1.5 (1-4) 0.005Mean HCT-CI (range) 1.7 (0-11) 1.9 (0-7) 0.65
(Continued )
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(79 pts)No HCT
(38 pts)P-value
logistic
regressionUnfavorable cytogenetics (n) 30 (37%) 7 (18%) 0.18
Secondary AML (n) 39 (49%) 15 (39%) 0.32
Early relapse (n) (>5%
marrow blasts within
4.9 months of CR1
(range 0.9-10, median 3.75)0 (0%) 13 (34%) <0.001Twenty-four of the 38 (63%) non-HCTpatients wereHLA-typed
and matched donors were found for 13 of these 24 patients (54%; 5
related, 8 unrelated). Seven of the 14 non-typed patients (50%) had
financial barriers or refusedHLA-typing. Only 2 of these 38 (5%) re-
ceived HCT beyond CR1.
Conclusion: These data suggest that HCT can be performed in
CR1 in the majority of high-risk AML patients in whom it is cur-
rently recommended. Patients in whom HCT is not done are char-
acterized by a poorer performance status (but not older age) and by
early relapse. In the absence of these 2 factors,.75%of patients with
high-risk AML under the age of 75 can receive HCT in CR1. A na-
tional study is planned to assess the extent to which these results can
be generalized.229
CLINICAL TRIAL EVALUATING DC/AML FUSION CELL VACCINATION
ALONE AND IN CONJUNCTION WITH PD-1 BLOCKADE IN AML PATIENTS
WHO ACHIEVE A CHEMOTHERAPY-INDUCED REMISSION
Rosenblatt, J.1, Stone, R.2, Avivi, I.3, Uhl, L.1, Neuberg,D.2, Joyce, R.M.1,
Tzachanis, D.1, Levine, J.D.1, Boussiotis, V.1, Zwicker, J.1, Arnason, J.1,
Luptakova, K.1, Steesma, D.2, DeAngelo, D.2, Galinsky, I.2, Vasir, B.2,
Somaiya, P.1, Mills, H.1, Yuan, E.1, Bonhoff, J.1, Delaney, C.1,
Drummy, N.1, Nicholson, L.2, Stroopinsky, D.1, Held, V.3, Katz, T.3,
Rowe, J.3, Kufe, D.2, Avigan, D.E.1 1Beth Israel Deaconess Medical Cen-
ter, Boston, MA; 2Dana-Farber Cancer Institute, Boston, MA; 3Rambam
Medical Center, Haifa, Israel
A promising area of investigation in AML is the development of
cancer vaccines that educate host immunity to target leukemia cells,
including the stem cell compartment. Our group has developed
a cancer vaccine in which dendritic cells (DCs) are fused to autolo-
gous tumor cells, resulting in the presentation of multiple tumor an-
tigens and eliciting a broad immune response. A challenge to
developing a more effective tumor vaccine is overcoming inhibitory
pathways, including the PD1/PDL1 pathway, contributing to tu-
mor-mediated immune suppression. We are conducting a clinical
trial in which AML patients who are in remission following chemo-
therapy receive three monthly doses of DC/AML fusion cells alone
(cohort 1) or in conjunction with anti-PD1 antibody, CT-011 (co-
hort 2). To date, 21 patients (mean age 57 years) have been enrolled.
Patients underwent tumor collection from either bone marrow (N5
14), 20 cc of peripheral blood (N 5 5), or leukapheresis product
(N 5 2). The mean tumor yield and viability was 8.43x108 cells
and 99% respectively. Patients achieving remission following che-
motherapy underwent leukapheresis for DC generation. Adherent
peripheral blood mononuclear cells were cultured in the presence
of GM-CSF and IL-4 for 5-7 days, and exposed to TNFa for 48
hours to generate mature DCs. One patient died during induction
chemotherapy, one patient did not collect a sufficient number of tu-
mor cells for vaccine generation, and 3 patients were removed from
study to undergo allogeneic transplantation. Vaccine was generated
in 12 patients at a dose of 5x106 fusions cells, mean fusion efficiency
of 31%, and viability of 87%. As ameasure of their activity as antigen
presenting cells, the capacity of fusion cells to stimulate allogeneic T
cell proliferation ex vivo was quantified. In contrast to the leukemia
cells (mean stimulation index (SI) 4.4), the DC and fusion cells were
potent stimulators (mean SI 24.1 and 15.5, respectively). Vaccination
was initiatedwithin 12 weeks from count recovery following comple-
tion of chemotherapy. 4 patients have completed vaccinations, and 3
are undergoing vaccination. Vaccine related adverse events includedvaccine site reactions, ankle pain and edema. Biopsy of a vaccine site
reaction demonstrated a dense T cell infiltrate. Peripheral blood is
being collected prior to and serially following vaccination. Immune
response targeting leukemia cells, leukemic stem cells, and leukemia
associated antigens will be assessed.230
EARLY RESULTS OF A PHASE II STUDY ADDING PERI-TRANSPLANT RIT-
UXIMAB TO NONMYELOABLATIVE CONDITIONING AND ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS (PTS)
WITH HIGH-RISK FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)
Sorror, M.L.1,2, Storer, B.1,2, Sandmaier, B.M.1,2, Chauncey, T.1,2,3,
Bruno, B.4, Andersen, N.N.S.5, Hogan, W.J.6, Storb, R.1,2,
Maloney, D.1,2 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA; 3Seattle Veterans Administra-
tion Medical Center, Seattle, WA; 4University of Torino, Torino, Italy;
5The Rigshospitalet, Copenhagen, Denmark; 6Mayo Clinic, Rochester,
MN
CLLpts who are fludarabine-refractory or possess unfavorable cy-
togenetics have short survivals with conventional therapies. Non-
myeloablative allogeneic HCT may provide long-term disease
control. Disease progression is the major risk within the first year
after HCT (median 3.3 months), until development of graft-versus-
leukemia (GVL) effects. Treatment with anti-CD20monoclonal an-
tibody (rituximab) in the early post-transplant period could improve
disease control: 1) directly by antibody-dependent cytotoxicity and
2) indirectly by promoting cross-presentation of cell-derived pep-
tides causing earlier and/or more robust GVL effects. To date, 20
pts have been enrolled on a phase II trial comprising fludarabine,
30 mg/m2 (days -4, -3, and -2) and 2 Gy total body irradiation (day
-1) together with rituximab, 375 mg/m2 (days -3, +10, +24, and
+38). Grafts were from HLA-matched related (n 5 6) or unrelated
(n 5 14) donors. Median age was 61 (range 37-74) years. Pts were
older, had higher comorbidity scores, more frequently received un-
related grafts, and more frequently had unfavorable cytogenetics
compared to a historical control group of 128 pts treated with the
same regimen except for peri-transplant rituximab (Table).
Table. Comparison of Pre-transplant Characteristics Among
Pts Treated with Nonmyeloablative Conditioning and Alloge-
neicHCTEitherWith (n520) orWithout (n5128)Rituximab
No Rituximab Rituximab
(n 5 128),
n (%)
(n 5 20),
n (%) pAge, years $60 32 (26%) 14 (70%) 0.0001
0 51 (32%) 2 (10%)HCT-CI scores 1-2 42 (37%) 7 (35%) 0.05
$3 35 (31%) 11 (55%)Response to last
treatment
prior to HCTRelapse/
refractory73 (57%) 12 (60%) 0.80CR or PR 55 (43%) 8 (40%)
Fludarabine-refractory Yes 117 (91%) 20 (100%) 0.17
Lymph node size
$5 cmYes 33 (26%) 6 (30%) 0.69Campath within
12 months prior
to HCTYes 30 (23%) 5 (25%) 0.88Donor type Unrelated 55 (43%) 14 (70%) 0.02
Chromosomal
abnormalities
Unfavorable* 50 (64%) 19 (95%) 0.0002Favorable† 78 (36%) 1 (5%)*Includes deletion 17p, P53 mutation, deletion 11q23, or more than 3
cytogenetic abnormalities.
†Includes deletion 13q, normal chromosomes, and triosomy 12.
After a median follow up of 13.6 (range: 3.4-26.5) months follow-
ing HCT, none of the 20 pts have experienced progression or
